Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA® in ppFEV1 and further improvement of CFTR function as measured by sweat chloride Real-world evidence and clinical studies of TRIKAFTA®… Read More
TORONTO, ON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor, a once-daily triple combination therapy for people living… Read More
SYRACUSE, NY, VANCOUVER, BC & BASEL, CH —Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company… Read More
Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score… Read More
National competition, in collaboration with SpinUp, the University of Toronto’s lab-based life sciences accelerator, demonstrates AbbVie’s commitment to a thriving biotech ecosystem in Canada One Canadian biotech will receive a… Read More
